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A biological function based 
biomarker panel optimization 
process
Min Young Lee, taek-Kyun Kim, Kathie-Anne Walters & Kai Wang
Implementation of multi-gene biomarker panels identified from high throughput data, including 
microarray or next generation sequencing, need to be adapted to a platform suitable in a clinical setting 
such as quantitative polymerase chain reaction. However, technical challenges when transitioning 
from one measurement platform to another, such as inconsistent measurement results can affect 
panel development. We describe a process to overcome the challenges by replacing poor performing 
genes during platform transition and reducing the number of features without impacting classification 
performance. This approach assumes that a diagnostic panel reflects the effect of dysregulated 
biological processes associated with a disease, and genes involved in the same biological processes and 
coordinately affected by a disease share a similar discriminatory power. The utility of this optimization 
process was assessed using a published sepsis diagnostic panel. substitution of more than half of the 
genes and/or reducing genes based on biological processes did not negatively affect the performance 
of the sepsis diagnostic panel. our results suggest a systematic gene substitution and reduction 
process based on biological function can be used to alleviate the challenges associated with clinical 
development of biomarker panels.
Multi-gene biomarker panels identified from gene expression data can be used to diagnose diseases and/or strat-
ify patients into different disease stages. Machine learning and data mining algorithms have been adapted to 
identify biomarker candidates. The general workflow for transcript-based biomarker panel discovery includes 
identifying disease-affected genes (e.g. differentially expressed genes), selecting a subset of genes (features) for 
the panel, and building a classifier (decision rule) based on the selected features. Various feature selection meth-
ods (recursive feature elimination (RFE), least absolute shrinkage and selection operator (LASSO) method, and 
the Boruta and Vita approaches) have been used1–3 by considering feature decencies and interaction with clas-
sification methods such as support vector machine (SVM), logistic regression (LR), and random forest (RF) 
that have been widely applied to build diagnostic panels to discriminate between states4. Based on this general 
approach, many biomarker panels have been reported in the literature but few have been successfully devel-
oped into clinical assays5,6. In part, this is due to the technical difficulties during the transition from discovery 
to development phase. To implement transcript based biomarkers that were identified from high-throughput 
transcriptomic data such as microarray or next generation sequencing (NGS), the transcripts (features) need 
to be measured with a platform that is more suitable for use in a clinical setting such as quantitative polymerase 
chain reaction (qPCR)7,8. However, there are technical challenges when moving from high-throughput platforms 
into different measurement methods like qPCR. A major issue is the inconsistency of results between different 
measurement platforms9–11. It is also a challenge to develop a panel with 30 or 40 features for clinical use due to 
cost and implementation12.
To identify a candidate biomarker panel with a limited number of features, Top Scoring Pair (TSP) is poten-
tially useful13. The goal of TSP is to identify a pair of genes where the ordering (i.e. the relative expression) of two 
genes is reversed between groups. TSP is then extended to kTSP, k pairs of genes, to achieve a higher performance 
through additional pairs of genes14. To address the inconsistency between measurement platforms15, demon-
strated that poor performing features (genes) in a 17 gene panel for predicting clinical outcome of breast cancer 
patients can be substituted with highly correlated genes in the same pathway15. Additionally, the authors showed 
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that the number of features in the panel can be reduced, although the original 17 gene panel remained the best 
predictor.
In this study, we describe a systematic process to optimize transcript based biomarker panels by both replacing 
poor performing genes (features) and reducing the number of features in the panel. The approach is based on the 
similar hypothesis described by Liu et al. in that a diagnostic panel measures the combined effect of dysregulated 
biological processes during the development of a disease and that highly correlated genes involved in the same 
biological processes should share similar discriminatory power. We further filtered substitution candidates by 
selecting those that have the same directional changes of its concentrations in the disease, rather than simply 
the highest correlated gene. The complex regulatory network in a biological system coordinately affects multiple 
genes relating to the phenotype that can be equivalent to each other for discriminating the phenotype16. This 
biological function-based gene substitution provides a solution for gene measurement issues encountered during 
platform transition. Our approach can also be used to reduce the features in a diagnostic panel by identifying a 
minimal set of genes to represent core biological processes in a multi-gene biomarker panel.
The utility of the biomarker optimization process was demonstrated using a published sepsis diagnostic panel, 
referred to here as the Stanford11 gene panel17. We investigated (1) critical biological pathways associated with the 
Stanford11 gene panel, (2) the impact of gene substitution on the diagnostic performance of the Stanford11 gene 
panel, and (3) minimal core genes required for the diagnostic panel. We showed that substitution and reduction 
of more than half of the Stanford11 does not affect the performance. Multiple alternative panels with less features 
compared to the Stanford11 were identified, but have equivalent diagnostic performance. The results suggest a 
systematic gene substitution and reduction process can be used to alleviate the challenges associated with trans-
lation of candidate biomarker panels into clinically applicable assays without sacrificing the performance of a 
biomarker panel.
Results
Identification of substitutable genes for the Stanford11 sepsis diagnosis panel. The overall pro-
cedure and the results of identifying substitutable genes for Stanford11 are summarized in Fig. 1A. There were 
503 gene ontology biological processes (GOBPs) represented by at least one of the 82 differentially expressed 
genes (DEGs) termed Stanford82. The genes in the Stanford11 panel were involved in 97 different GOBPs, with 
the exception of ZDHHC19 and KIAA1370 which are not associated with known biological function. Among 
the 97 GOBPs associated with Stanford11, 27 of them had at least one additional gene from the Stanford82 gene 
pool that is not in the Stanford11 panel and can be used as potential substitution candidates. These 27 GOBPs 
are represented by six key biological processes; (1) chemotaxis, adhesion, migration; (2) antigen processing, 
immune response; (3) transcription by pol II; (4) platelet activation; (5) apoptosis; and (6) metabolism (Fig. 1B). 
We summarized substitution candidates that are involved in these 6 key biological processes associated with 
the Stanford11 panel (Table 1). Among the six key biological processes, two processes, chemotaxis, adhesion, 
migration and platelet activation, have more than two genes in the panel and the remaining four processes have 
just one gene. RPGRIP1, a gene associated with neural precursor cell proliferation and retina development, is 
substitutable only with the genes already included in the Stanford11 panel and so was excluded for gene substi-
tution. Among the substitutable genes, only genes with the same directional changes as genes in the Stanford11 
panel, i.e., increased or decreased expression level in sepsis patients compared to controls were selected. Among 
Figure 1. Identification of substitutes for Stanford11. (A) The overall procedure of the identification of 
substitutes for Stanford11. (B) The six key biological processes represented by the Stanford11 panel.
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the 28 substitution candidates, 20 genes were retained for six genes in the Stanford11 panel (CEACAM1, C3AR1, 
GNA15, BATF, MTCH1, and C9orf95) representing five biological functions. TGFBI (GOBP chemotaxis, angi-
ogenesis, adhesion, migration) was removed since no substitutable gene with the same directional change was 
retained. There was also no substitutable gene for HLA-DPB1 (immune response function); therefore, HLA-
DPB1 was retained to keep all six biological processes during substitution and reduction procedures. Interestingly, 
most of the six genes that can be substituted in the Stanford11 panel showed increased expression level in sepsis 
patients except MTCH1, a gene involved in apoptosis (Table 1).
Since three genes (ZDHHC19, KIAA1370, and RPGRIP1) were excluded during the process of identification 
of substitutable genes, their contribution to the classification performance (defined as area under the curve, AUC) 
of Stanford11 was assessed. Interestingly, excluding these genes from Stanford11 did not significantly affect the 
performance in both discovery and validation sets (Supplementary Table S3). In the case of excluding all three 
genes, the performance decreased in one discovery and one validation set (Glue grant day [1–3] from 0.9145 to 
0.865 and GSE74224 from 0.8814 to 0.8544) while increasing in one discovery set (GSE40012 from 0.7091 to 
0.774). Therefore, the three genes contributed marginally to the diagnostic performance of Stanford11.
Importance of biological processes on classification performance. To determine the impact of bio-
logical processes in the performance of a diagnostic panel, we generated 100,000 panels consisting of 11 genes 
randomly selected from the Stanford82 list. The classification performances of the 100,000 random 11 member 
gene sets in the nine discovery datasets were computed and sorted based on the performance as measured by 
AUC (Fig. 2A). The GOBP associated with genes in the top 250 and bottom 250 gene sets were summarized 
in Fig. 2B. The GOBPs represented by the top 250 gene sets were similar to the Stanford11 six key processes 
(Fig. 2B), such as transcription by pol II (cluster 1 and 2 in Fig. 2B,C), phosphorylation (cluster 4), apoptosis 
(cluster 5), PLC (cluster 6), chemotaxis (cluster 7), antigen processing and presentation (cluster 11), metabolic 
Chemotaxis, adhesion, 
migration
Antigen processing, 
immune response
Transcription 
by RNA pol II
Platelet 
activation Apoptosis Metabolism
CEACAM1↑
ADAMTS3↑,
CCR1↑,
CD177↑,
CD63↑,
EMR1↑,
FCER1G↑,
IL10↑,
OSTalpha↑,
PSTPIP2↑,
SIGLEC9↑,
TBC1D4↓
C3AR1↑
ANXA3↑,
CCR1↑,
CD177↑,
EMR1↑,
FCER1G↑,
FES↑,
FFAR3↑,
IL10↑,
S100A12↑
GPR84↑
TGFBI↓
CCR1↑,
EMR1↑,
FES↑,
SIGLEC9↑
GNA15↑
CCR1↑,
EMR1↑,
FFAR3↑
FCER1G↑,
P2RX1↑
HLA-DPB1↓
BPI↑, CCR1↑,
FCER1G↑,
FCGR1B↑,
IL10↑,
IL18R1↑
BATF↑
IL10↑,
PLAC8↑,
GLO1↓,
PRKRIR↓,
WDR75↓
MTCH1↓
LCN2↑,
OSTalpha↑,
P2RX1↑,
ARHGEF18↓
C9orf95↑ C9orf103↑,SEPHS2↑
Table 1. The list of substitutable genes for features in the Stanford11. Substitution candidates (n = 28) for 
eight genes of Stanford11 were selected based on six key biological processes. ↑ And ↓ indicates increased or 
decreased expression level in sepsis, respectively. No substitutable gene was retained for TGFBI and HLA-DPB1 
after considering consistency in directional changes.
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process (cluster 13). Interestingly, the neural precursor cell proliferation and retina development process in clus-
ter 3 was also frequently involved in high performing gene sets. RPGRIP1, which has no substitutable gene, was 
involved in this biological process. However, removing RPGRIP1 from Stanford11 did not significantly decrease 
diagnostic performances as shown in Supplementary Table S3. It suggests that genes involved in this biological 
process have discriminating power but are not essential to retain classification performance of gene panels.
Impact of gene substitution on classification performance. A total of 12 microarray datasets from 
the public domain were used to evaluate the effect of gene substitution/reduction on the diagnostic performances 
of Stanford11. Nine of the datasets were used in the original discovery of the Stanford11 gene panel. The other 
three, GSE65682, GSE74224 and E-MTAB-3589, were not used in the development of Stanford11 panel; there-
fore, they were used as independent validation data in this study.
Based on the substitution candidates listed in Table 1, we changed one gene at a time for the six substitutable 
genes in the Stanford11 panel. As shown in Fig. 3A–F, one gene substitution does not affect the overall diagnostic 
performance in both the nine discovery and three validation datasets. In discovery datasets, the average AUCs 
of the substitutions were not significantly lower than the original Stanford11 panel except using the GSE74224 
dataset when replacing GNA15 (Fig. 3E).
We then tested the effect of substituting genes representing all functional categories simultaneously. If a func-
tion had more than one substitutable gene, all combinations of genes were enumerated and their classification 
performances were tested and summarized in Fig. 4. Except for the GSE40012 and GSE66099 datasets used in 
the Stanford11 discovery process, there were multiple five gene substitutions that showed similar performances 
as the original Stanford11. In summary, gene substitution based on the same biological process and direction of 
concentration changes can provide alternative panels that have similar diagnostic performance.
Impact of gene reduction on classification performance. The possibility of using representative genes 
from each biological process to reduce the number of features in the diagnostic panel was investigated. Among 
the six representative biological processes of the Stanford11 panel, two biological functions have more than one 
gene in the panel. The GOBP, “platelet activation function” has two genes (C3AR1 and GNA15) and “chemotaxis, 
adhesion, migration function” has four genes (CEACAM1, C3AR1, TGFBI, and GNA15) in the panel. The AUCs 
of panels where only one gene was retained were calculated. As shown in Fig. 5A, the two panels with only one 
gene retained from “platelet activation function” have similar performance to the Stanford11. The panels with 
only one gene from the GOBP “chemotaxis, adhesion, migration function” also have similar performance in the 
datasets used to identify Stanford11 (Fig. 5B). The impact of retaining only one gene from both GOPBs was tested 
and the average diagnostic performance was not significantly different from the original Stanford11 panel in all 
the discovery and validation sets (Fig. 5C). In all cases, there were multiple panels with reduced features that 
delivered better performances in more than half of the independent validation datasets.
To explore the possibility of just using representative genes from key biological processes associated with 
Stanford11, all possible combinations of six gene panels were generated from genes mapped to those six biological 
Figure 2. Importance of biological processes on classification performance. (A) The distribution of 
classification performances of the 100,000 random gene sets. (B) The number of genes of the top and bottom 
250 gene sets in 97 GOBPs represented by Stanford11. (C) Clusters of GOBPs in the top 250 and bottom 250 
gene sets. Count and percent indicate the average number and percentage of genes in each GOBP cluster.
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processes. Diagnostic performances for all six-gene combinations were computed (Fig. 6). Among the 1,482 
six-gene combinations, 73 new panels which have higher performance than the lower bound of 95% confidence 
intervals in all discovery datasets than the original panel were selected (Supplementary Table S4). Among the 
73 new panels, 22 panels have higher performance even in the two validation sets (GSE65682 and GSE74224, 
Table 2).
Addition of RPGRIP1 to the new six-gene panels. Though removing RPGRIP1 (neural precursor cell 
proliferation and retina development process) from the original Stanford11 panel did not decrease the overall 
diagnostic performance (Supplementary Table S3), we tested the effect of adding RPGRIP1 to the new 6 gene 
panels. The results showed that adding RPGRIP1 to the 6-gene panel only improved the performance in one of 
the validation datasets, GSE74224, but not in the other two datasets (Supplementary Table S5).
Figure 3. The performances of one gene substitution. The distribution of AUCs in the 12 microarray datasets 
when (A) BATF; (B) C3AR1; (C) C9orf95; (D) CEACAM1; (E) GNA15; (F) MTCH1 was replaced with a 
substitute gene. *Indicates P-value from DeLong test comparing a substituted panel (blue bars) with the median 
AUC and the original Stanford11 (gray bars) less than 0.05.
Figure 4. The performances of five gene substitution. The AUCs in the 12 microarray datasets when genes 
representing all five functional categories were replaced with substitute genes. *and **indicate P-value from 
DeLong test comparing a substituted panel with the median AUC and the original Stanford11 less than 0.05 and 
0.01, respectively.
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evaluation of the impact of biological function information. The performance differences between 
biological function-based and expression correlation-based substitution were tested. Based on expression profiles 
of all the discovery datasets, the highest correlated genes with features in the Stanford11 were selected (referred 
to as Panel-HC) regardless of the biological functions (Table 3). Most of the highest correlated genes with features 
in the Stanford11 were not from Stanford82 nor involved in the same GOBPs represented by Stanford11. For 
instance, BATF of Stanford11 is involved in transcription by pol II, but the highest correlated gene, DDAH2 is 
involved in nitric oxide biosynthetic process. The average AUCs of the Panel-HC in the discovery and validation 
sets were 0.8238 and 0.6846 which are 3.58% and 14.40% lower than the Stanford11 (average AUC of 0.8544 and 
0.7997 in the discovery and validation sets, respectively (Fig. 7A). This suggests maintaining biological processes 
associated with disease condition is more critical to generating high performance diagnostic panels than main-
taining features with highly correlated expression profiles.
By randomly selecting 11 out of 14 genes involved in adhesion/migration process, 364 panels were generated 
(referred to as Panel-AM) (Table 3). The performances of Panel-AM were also lower than Stanford11 (average 
AUC of 0.7999 and 0.7546 in the discovery and validation sets, respectively, Fig. 7B) which suggests genes from 
one biological process do not deliver sufficient diagnostic performance.
We further test the feasibility of using existing algorithms to optimize the panel. Among various wrapper 
approaches, SVM-RFE and LR-LASSO were applied. Ten (referred to here as the Panel-SVM) and six genes 
(Panel-LR) were obtained from the Stanford11 genes by the SVM-RFE and LR-LASSO approaches, respec-
tively (Table 3). The classification performance of the two panels was not significantly different from the original 
Stanford 11 panel (Fig. 7C,D). The SVM-RFE approach did not effectively reduce the number of genes in the 
panel. The LR-LASSO resulted in a 6 gene panel with similar performance as original Stanford11 panel; there-
fore, it might be a useful approach to optimize gene panels. However, both approaches can only down-select 
genes from an existing panel and cannot provide any substitutable genes if any of the original genes fails in assay 
development process. kTSP algorithms were also applied to identify classifiers with a small set of paired genes. 
Figure 5. The performances of gene reduction. The AUCs in the 12 microarray datasets when only one gene 
in (A) platelet activation function; in (B) chemotaxis, adhesion, migration function; (C) in both processes was 
retained. *and **indicate P-value from DeLong test comparing a substituted panel with the median AUC and 
the original Stanford11 less than 0.05 and 0.01, respectively.
Figure 6. The performances of 1,482 six-gene combinations. *and **indicate P-value from DeLong test 
comparing a substituted panel with the median AUC and the original Stanford11 less than 0.05 and 0.01, 
respectively.
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It resulted in three pairs which including six genes in total (referred to as Panel-kTSP, Table 3). The Panel-kTSP 
showed significantly lower performance in independent datasets (AUC < 0.6 and p-value from DeLong’s test of 
less than 0.01 in two validation data sets in Fig. 7E). Therefore, the kTSP approach failed to provide a panel with 
good classification performance. In addition, similar to the SVM-RFE and LR-LASSO approaches, kTSP cannot 
provide alternative genes.
Discussion
There are two main considerations when validating and developing a biomarker panel: (1) the measurement 
inconsistency when transitioning from one measurement platform (for example, microarray) to another (such 
as qPCR), and (2) the number of features in the panel. Neither revisiting the discovery phase (identifying DEGs, 
feature selection, and using different computational approaches) to generate new panel(s) nor examining all pos-
sible combinations of DEGs already discovered can overcome these challenges. In the case of Stanford11 panel, to 
6-gene 
Panels
Chemotaxis, 
adhesion, 
migration
Antigen 
processing, 
immune response
Transcription by 
RNA pol II
Platelet 
activation Apoptosis Metabolism GSE65682 GSE74224 E-MEXP-3589
1 CCR1 HLA-DPB1 BATF C3AR1 ARHGEF18 C9orf95 0.7807 0.8854 0.6633
2 CCR1 HLA-DPB1 BATF C3AR1 MTCH1 C9orf103 0.8170 0.9058 0.6990
3 CCR1 HLA-DPB1 BATF C3AR1 MTCH1 C9orf95 0.8095 0.8967 0.6786
4 CCR1 HLA-DPB1 BATF GNA15 MTCH1 C9orf95 0.8080 0.8893 0.6378
5 CD177 HLA-DPB1 BATF C3AR1 MTCH1 C9orf95 0.8014 0.8827 0.6684
6 CD63 HLA-DPB1 PLAC8 FCER1G MTCH1 C9orf95 0.8158 0.9128 0.6122
7 CD63 HLA-DPB1 PLAC8 GNA15 ARHGEF18 C9orf95 0.7852 0.9220 0.5663
8 CD63 HLA-DPB1 PLAC8 GNA15 MTCH1 C9orf95 0.8107 0.9333 0.5918
9 CD63 HLA-DPB1 BATF C3AR1 MTCH1 C9orf95 0.8080 0.9067 0.6633
10 CD63 HLA-DPB1 BATF GNA15 MTCH1 C9orf95 0.8029 0.8915 0.6378
11 EMR1 HLA-DPB1 BATF C3AR1 MTCH1 C9orf95 0.8149 0.8963 0.6582
12 EMR1 HLA-DPB1 BATF GNA15 MTCH1 C9orf95 0.8044 0.8836 0.6071
13 FCER1G HLA-DPB1 PLAC8 C3AR1 MTCH1 C9orf95 0.8080 0.9241 0.6531
14 FCER1G HLA-DPB1 PLAC8 GNA15 ARHGEF18 C9orf95 0.7861 0.9098 0.5408
15 FCER1G HLA-DPB1 PLAC8 GNA15 MTCH1 C9orf95 0.8092 0.9185 0.5816
16 FCER1G HLA-DPB1 BATF C3AR1 MTCH1 SEPHS2 0.8086 0.8867 0.6582
17 FCER1G HLA-DPB1 BATF C3AR1 MTCH1 C9orf95 0.8071 0.8963 0.6480
18 FES HLA-DPB1 PLAC8 FCER1G MTCH1 C9orf95 0.8089 0.8945 0.6173
19 FES HLA-DPB1 PLAC8 GNA15 ARHGEF18 C9orf103 0.7870 0.9098 0.6122
20 FES HLA-DPB1 PLAC8 GNA15 MTCH1 C9orf95 0.8005 0.9150 0.6071
21 FES HLA-DPB1 BATF C3AR1 MTCH1 C9orf95 0.8026 0.8806 0.6786
22 C3AR1 HLA-DPB1 BATF GNA15 MTCH1 C9orf95 0.7999 0.9133 0.6480
Table 2. Optimized six-gene panels (n = 22) with higher performance in the validation sets. Among six gene 
panels (n = 73) that have higher performance than the lower bound of 95% confidence intervals of the original 
Stanford11 panel in all discovery datasets, 22 panels have even higher performance in two independent datasets.
The 11 highest correlated genes
Chemotaxis, adhesion, 
migration processes SVM-RFE LR-LASSO
k-Top Scoring 
Pairs
Stanford11 Panel-HC CC
Stanford 
82 14 genes 10 genes 6 genes 6 genes
BATF DDAH2 0.7642
C3AR1, CD177, FCER1G, 
CEACAM1, ADGRE1, 
CCR1, TGFBI, SIGLEC9, 
CD63, PSTPIP2, FES, 
ANXA3, IL10, RETN
BATF, TGFBI, GNA15, 
C9orf95, MTCH1, 
C3AR1, ZDHHC19, 
KIAA1370, RPGRIP1, 
CEACAM1
BATF, C3AR1, 
C9orf95, 
GNA15, 
MTCH1, 
TGFBI
TGFBI - C3AR1
GNA15 - 
CEACAM1
RPGRIP1 - 
ZDHHC19
C3AR1 SQRDL 0.5393 √
C9orf95 PTPN22 0.4870
CEACAM1 GPR84 0.8169 √
GNA15 FERMT3 0.5874
ZDHHC19 GPR84 0.7408 √
HLA-DPB1 HLA-DMB 0.7329
KIAA1370 KIAA1468 0.6517
MTCH1 CDK5RAP3 0.6607
RPGRIP1 NOV 0.5266
TGFBI CPVL 0.8078
Table 3. Genes used in evaluation of the impact of biological function information. √ in Stanford82 column 
indicates the genes of Stanford82. CC indicates the Pearson’s correlation coefficient between the genes.
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identify alternative 11 gene panels from the Stanford82 is computationally challenging, since there are 1.4e + 13 
possible combinations of 11 gene panels from the Stanford82 genes. To assess the performance of these panels 
would take 32,407 days even on a 100 node cluster computer (based on estimated calculation time per one com-
bination for 12 datasets: 0.02 seconds). To address these challenges, we used a systematic process to reduce the 
number of features and to replace poor performing genes in the panel with other differentially expressed genes 
with similar biological function. The fact that features are substitutable, based on similar trend of expression 
changes and biological function, leads to the conclusion that the performance of a biomarker panel has more 
to do with its connection to disease-perturbed networks than to the specific genes themselves. The result of this 
feature substitution method is a number of different panels comprising only six genes, with performances at least 
as high as the original 11 gene panel.
There has been a discussion on the multiplicity of disease signatures16,18. Different computational and math-
ematical algorithms, noisy measurements, and/or different data pre-processing procedures result in different 
molecular signatures. Some studies also suggested that overfitting and/or artifacts from data analyses also yield 
different molecular signatures19. On the other hand, others have proposed that the multiplicity attributes to the 
complex regulatory networks of the biological system leading to multiple biomarker sets that are equally pre-
dictive. Statnikov et al. showed that numerous signatures can be identified regardless of microarray platforms, 
pre-processing methods, and model algorithms suggesting that intrinsic gene-gene and gene-phenotype relations 
might be a source of multiplicity16. Our results also support this hypothesis by showing that genes involved in the 
same biological process are interchangeable and share similar discriminatory power.
In conclusion, this study showed a multigene biomarker panel can be optimized through systemic gene sub-
stitution and reduction based on biological function information. The method outlined here can be applied to 
identify alternative panels for other multigene/protein based biomarkers for numerous diseases and may facilitate 
developing clinically applicable assays by alleviating challenges in transitioning from high-throughput measure-
ment platform to other platforms.
Methods
sepsis Metascore. The Stanford11 gene panel (CEACAM1, ZDHHC19, C9orf95, GNA15, BATF, C3AR1, 
KIAA1370, TGFBI, MTCH1, RPGRIP1, and HLA-DPB1) was developed by first identifying 82 differentially 
expressed genes (DEGs) termed Stanford82 (Supplementary Table S2), from a meta-analysis of nine independent 
microarray datasets (Supplementary Table S1). The panel was generated using the greedy forward search method, 
an algorithm to assemble biomarker panels by identifying the best gene to classify samples and sequentially adds 
the next best genes to increase the classification score until maximum score is achieved. Classification of each 
sample was determined based on the Sepsis MetaScore (SMS) which was calculated according to the following 
equation20:
= × × × × ×
− × × × ×
SMS (CEACAM1 ZDHHC19 C9orf95 GNA15 BATF C3AR1)
5/6 (KIAA1370 TGFBI MTCH1 RPGRIP1 HLADPB1)
6
5
Figure 7. Evaluation of the impact of biological function information. The importance of biological function 
information was evaluated in five different approaches. (A) The AUCs of the Panel-HC. (B) The AUCs of the 
Panel-AM. (C) The AUCs of the Panel-SVM. (D) The AUCs of the Panel-LR. (E) The AUCs of the Panel-kTSP. 
*and **indicate p-value from DeLong test less than 0.05 and 0.01, respectively.
9Scientific RepoRts |          (2019) 9:7365  | https://doi.org/10.1038/s41598-019-43779-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
SMS is the difference between a geometric mean of up-regulated genes in sepsis and a geometric mean of 
down-regulated genes in sepsis. The same equation was applied to all alternative panels generated with gene sub-
stitution and reduction procedures described below. Classification power of SMS in each dataset was determined 
by the area under the curve (AUC) of receiver operating characteristic (ROC) curve. Two-sided 95% confidence 
intervals for AUC were computed using pROC R package21. Statistical significance of the difference between 
AUCs was computed with DeLong’s method.
Identification of substitutes for Stanford11. The list of substitutable genes in Stanford11 was generated 
based on gene ontology biological processes (GOBPs). We first analyzed the biological functions associated with 
the Stanford82 genes through functional enrichment analyses of GOBPs using DAVID (Database for Annotation 
Visualization and Integrated Discovery)22. We used GO Direct category which provides GO mappings directly 
annotated by the source database. The terms with ≥1 genes were selected as Stanford82 associated GOBPs. The 
GOBPs which included at least one of Stanford11 genes and with at least 2 genes were selected and visualized as 
a network using Enrichment Map v2.1.0, a Cytoscape plugin23. The connected GOBP terms were merged and 
defined as a single functional category. Genes involved in the merged GOBPs and having the same directional 
changes were defined as substitutable candidates in the same GOBP.
Microarray datasets. A total of 12 different microarray datasets were used in two studies by Sweeney et al. 
(Supplementary Table S1)20. The first nine datasets are the discovery set that was used to identify Stanford11 
and the last three datasets are independent validation sets. The microarray datasets were normalized by the 
same methods used by Sweeney et al. Briefly, Affymetrix datasets were normalized using the Robust Multi-array 
Average (RMA) or GC-RMA (R package affy)24. Agilent and Illumina datasets were background corrected based 
on normal-exponential convolution model and then between-arrays quantile normalized using R package 
limma25. The mean of multiple probes for common genes was used as the gene expression level after normaliza-
tion. In the case of GSE74224, there was no probe for KIAA1370 in Stanford11; therefore, only 10 genes were used 
to compute the performance of Stanford11 for this data.
Gene substitution and reduction procedure. In order to systematically evaluate the effect of gene sub-
stitution and reduction on classification performance, five different procedures were used as follows: (1) substitute 
one gene at a time; (2) substitute all possible genes; (3) retain one gene for a GOBP where more than two genes are 
involved; 4) reduce panel by selecting one gene in each GOBP.
evaluation of the impact of biological function information. Five different approaches were used 
to evaluate the impact of biological function based optimization process on classification performance: (1) use 
the 11 highest correlated genes based on the expression profiles in the Stanford11 panel regardless of their bio-
logical functions; (2) use 11 randomly selected genes involved in chemotaxis, adhesion and migration biological 
function – one of GOBP terms associated with Stanford11; (3) Support Vector Machine with Recursive Feature 
Elimination (SVM-RFE)3; (4) Logistic Regression with Least Absolute Shrinkage and Selection Operator regular-
ization (LR-LASSO)26; and (5) k-Top Scoring Pairs classifier (kTSP) using switchbox R package to identify a small 
set of paired genes27. The AUC of kTSP was calculated by defining the number of votes among k pairs as a diag-
nostic score28. The 9 microarray data in the discovery set were co-normalized using COmbat CONormalization 
Using conTrols (COCONUT) R package prior to applying SVM-RFE and LR-LASSO to remove batch effect 
between different studies29. The chemotaxis, adhesion and migration GOBP terms were selected as they contain 
more than 11 genes that can be fully substituted for Stanford 11 genes. We also tested the classification perfor-
mance of randomly selected gene sets by generating 100,000 combinations of 11 genes randomly selected from 
the Stanford82 genes. We analyzed classification performance along with biological processes of the 100,000 
gene sets involved in. The top and bottom 250 gene sets in order of performance were selected. The hierarchical 
clustering was applied to cluster GOBPs based on the number of genes in each GOBP from the top and bottom 
250 gene sets.
Data Availability
The datasets analyzed in this study are available in the Gene Expression Omnibus (GEO) and ArrayExpress re-
positories. The accession numbers are included in the Supplementary Table S1. The code implementation used 
for biomarker gene panel optimization was uploaded to a GitHub repository, https://github.com/taekkyun/bio-
marker-panel-optimization.
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